Article
A polymorphism within IL21R confers risk for systemic lupus erythematosus.
Arthritis and rheumatism - 1 Aug 2009
Webb Ryan, Merrill Joan T, Kelly Jennifer A, Sestak Andrea, Kaufman Kenneth M, Langefeld Carl D, Ziegler Julie, Kimberly Robert P, Edberg Jeffrey C, Ramsey-Goldman Rosalind, Petri Michelle, Reveille John D, Alarcón Graciela S, Vilá Luis M, Alarcón-Riquelme Marta E, James Judith A, Gilkeson Gary S, Jacob Chaim O, Moser Kathy L, Gaffney Patrick M, Vyse Timothy J, Nath Swapan K, Lipsky Peter, Harley John B, Sawalha Amr H
Abstract excerpt
OBJECTIVE: Interleukin-21 (IL-21) is a member of the type I cytokine superfamily that has a variety of effects on the immune system, including B cell activation, plasma cell differentiation, and immunoglobulin production. The expression of IL-21 receptor (IL-21R) is reduced in the B cells of patients with systemic lupus erythematosus (SLE), while serum IL-21 levels are increased both in lupus patients and in some...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
